open access

Ahead of print
Research paper
Published online: 2021-04-07
Get Citation

Prognosis of gastric cancer patients with paraaortic lymph node metastasis versus those with distant metastases

Ho Gun Kim, Dong Yeon Kim, Jae Hyuk Lee, Dong Yi Kim
DOI: 10.5603/OCP.2021.0010

open access

Ahead of print
ORIGINAL ARTICLES
Published online: 2021-04-07

Abstract

Introduction. It has long been thought that cases of advanced gastric cancer with paraaortic lymph node (PALN) metastasis are impossible to cure. However, several recent reports on the long-term survival of patients with PALN metastasis have reported an increase in the use of gastrectomy with extended lymphadenectomy, involving the dissection of more nodes than those invaded by the tumour, as the standard surgery for advanced gastric cancer. 

Material and methods. The records of 1,015 patients with a confirmed histologic diagnosis of gastric cancer had been reviewed. Among patients with stage IV gastric cancer, 38 had PALN metastasis compared with 233 with peritoneal dissemination and 77 with hepatic metastasis. 

Results. Based on tumour location, metastasis to the PALNs was more common in upper-third cancer (p < 0.01); hepatic metastasis was more common in well-differentiated adenocarcinoma, and peritoneal dissemination was more common in poorly differentiated cancer (p < 0.001). The 5-year survival in patients with metastasis to the PALNs was significantly higher (28.2%) than in patients with peritoneal dissemination (5.2%) or hepatic metastasis (12.0%) (p < 0.01). 

Conclusions. The results reveal a better 5-year survival associated with gastric cancer patients with PALN metastasis as compared with those with other distant metastases. Therefore, performing a more extended lymphadenectomy in patients with gastric cancer is recommended, especially those with suspected metastasis to the PALNs.

Abstract

Introduction. It has long been thought that cases of advanced gastric cancer with paraaortic lymph node (PALN) metastasis are impossible to cure. However, several recent reports on the long-term survival of patients with PALN metastasis have reported an increase in the use of gastrectomy with extended lymphadenectomy, involving the dissection of more nodes than those invaded by the tumour, as the standard surgery for advanced gastric cancer. 

Material and methods. The records of 1,015 patients with a confirmed histologic diagnosis of gastric cancer had been reviewed. Among patients with stage IV gastric cancer, 38 had PALN metastasis compared with 233 with peritoneal dissemination and 77 with hepatic metastasis. 

Results. Based on tumour location, metastasis to the PALNs was more common in upper-third cancer (p < 0.01); hepatic metastasis was more common in well-differentiated adenocarcinoma, and peritoneal dissemination was more common in poorly differentiated cancer (p < 0.001). The 5-year survival in patients with metastasis to the PALNs was significantly higher (28.2%) than in patients with peritoneal dissemination (5.2%) or hepatic metastasis (12.0%) (p < 0.01). 

Conclusions. The results reveal a better 5-year survival associated with gastric cancer patients with PALN metastasis as compared with those with other distant metastases. Therefore, performing a more extended lymphadenectomy in patients with gastric cancer is recommended, especially those with suspected metastasis to the PALNs.

Get Citation

Keywords

gastric cancer; paraaortic lymph node; survival

About this article
Title

Prognosis of gastric cancer patients with paraaortic lymph node metastasis versus those with distant metastases

Journal

Oncology in Clinical Practice

Issue

Ahead of print

Article type

Research paper

Published online

2021-04-07

DOI

10.5603/OCP.2021.0010

Keywords

gastric cancer
paraaortic lymph node
survival

Authors

Ho Gun Kim
Dong Yeon Kim
Jae Hyuk Lee
Dong Yi Kim

References (23)
  1. Sobin LH. TNM classification of malignant tumors, 7th ed. UICC 2009.
  2. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14(2): 101–112.
  3. Inada T, Ogata Y, Ozawa I, et al. Long-term postoperative survival of a gastric cancer patient with numerous para-aortic lymph node metastases. Gastric Cancer. 1999; 2(4): 235–239.
  4. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol. 2004; 22(14): 2767–2773.
  5. Sasako M, Sano T, Yamamoto S, et al. D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer. N Engl J Med. 2008; 359(5): 453–462.
  6. de Manzoni G, Di Leo A, Roviello F, et al. Tumor site and perigastric nodal status are the most important predictors of para-aortic nodal involvement in advanced gastric cancer. Ann Surg Oncol. 2011; 18(8): 2273–2280.
  7. Wang Li, Liang H, Wang X, et al. Risk factors for metastasis to para-aortic lymph nodes in gastric cancer: a single institution study in China. J Surg Res. 2013; 179(1): 54–59.
  8. Morita S, Fukagawa T, Fujiwara H, et al. The clinical significance of para-aortic nodal dissection for advanced gastric cancer. Eur J Surg Oncol. 2016; 42(9): 1448–1454.
  9. Natsugoe S, Nakashima S, Matsumoto M, et al. Paraaortic lymph node micrometastasis and tumor cell microinvolvement in advanced gastric carcinoma. Gastric Cancer. 1999; 2(3): 179–185.
  10. Japanese Gastric Cancer Association. apanese gastric cancer treatment guidelines (ver.4). Kanehara publication, Tokyo 2014.
  11. Isozaki H, Okajima K, Fujii K, et al. Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. Hepatogastroenterology. 1999; 46(25): 549–554.
  12. Liang Yx, Liang H, Ding Xw, et al. [The prognostic influence of D2 lymphadenectomy with para-aortic lymph nodal dissection for gastric cancer in N3 stage]. Zhonghua Wai Ke Za Zhi. 2013; 51(12): 1071–1076.
  13. Hartgrink HH, van de Velde CJH, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004; 22(11): 2069–2077.
  14. Günther K, Horbach T, Merkel S, et al. D3 lymph node dissection in gastric cancer: evaluation of postoperative mortality and complications. Surg Today. 2000; 30(8): 700–705.
  15. Roviello F, Marrelli D, Morgagni P, et al. Italian Research Group for Gastric Cancer. Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study. Ann Surg Oncol. 2002; 9(9): 894–900.
  16. G D, A D, G B, et al. Envahissement des ganglions para-aortiques dans les adénocarcinomes de l'estomac. Annales de Chirurgie. 2001; 126(4): 302–307.
  17. Maeta M, Saito H, Kondo A, et al. Effects of super-extended paraaortic lymphadenectomy (PAL) on biological responses in totally gastrectomized patients with T3 or T4 gastric cancer. Gastric Cancer. 1998; 1(1): 57–63.
  18. Roviello F, Pedrazzani C, Marrelli D, et al. Super-extended (D3) lymphadenectomy in advanced gastric cancer. Eur J Surg Oncol. 2010; 36(5): 439–446.
  19. Inada T, Ogata Y, Andoh J, et al. Significance of para-aortic lymph node dissection in patients with advanced and recurrent gastric cancer. Anticancer Res. 1994; 14(2B): 677–682.
  20. Yoshizumi Y, Matuyama T, Koike H, et al. Long-term survival after gastric cancer and liver and paraaortic lymph node metastases: report of a case. Surg Today. 2001; 31(2): 159–162.
  21. Yonemura Y, Wu CC, Fukushima N, et al. East Asia Surgical Oncology Group. Metastasis in para-aortic lymph nodes in patients with advanced gastric cancer, treated with extended lymphadenectomy. Hepatogastroenterology. 2007; 54(74): 634–638.
  22. Tokunaga M, Ohyama S, Hiki N, et al. Can superextended lymph node dissection be justified for gastric cancer with pathologically positive para-aortic lymph nodes? Ann Surg Oncol. 2010; 17(8): 2031–2036.
  23. Kaito A, Kinoshita T, Tokunaga M, et al. Prognostic Factors and Recurrence Pattern of Far-advanced Gastric Cancer with Pathologically-positive Para-aortic Lymph Nodes. Anticancer Res. 2017; 37(7): 3685–3692.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl